Co-treatment of MEC cells with LB100 and cisplatin decreased PP2A activity to 84.98% of control levels in vitro. Combination-treated xenograft UM-HMC1 MEC mice also exhibited a significantly smaller tumor volume than did mice treated with either drug alone. The gene discussed is PTPA; the disease is neoplasm.